Fizazi, et al. ARAMIS: Efficacy and safety of darolutamide in nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO-GU 2019, abstract 140.
Adjuvant pembrolizumab bij volledig gereseceerd stadium IIB/IIC-melanoom
jul 2022 | Dermato-oncologie, Immuuntherapie